Skip to main content
SpringerLink
Log in

Identifying patients at risk for prostate-cancer-specific mortality: implications for clinical trial design

  • Practice Point
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bianco FJ Jr et al. (2005) Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 66 (Suppl 5): 83–94

    Article  Google Scholar 

  2. D'Amico AV et al. (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827

    Article  CAS  Google Scholar 

  3. D'Amico AV et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969–974

    Article  CAS  Google Scholar 

  4. Thompson IM Jr et al. (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296: 2329–2335

    Article  CAS  Google Scholar 

  5. D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125–135

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195-0001, USA stephea2@ccf.org

Authors and Affiliations

  1. AJ Stephenson is an Assistant Professor of Urology at the Cleveland Clinic Lerner College of Medicine and Associate Attending Staff in the Section of Urologic Oncology at the Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.,

    Andrew J Stephenson

Authors
  1. Andrew J Stephenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stephenson, A. Identifying patients at risk for prostate-cancer-specific mortality: implications for clinical trial design. Nat Rev Urol 4, 362–363 (2007). https://doi.org/10.1038/ncpuro0809

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0809

  • Springer Nature Limited

Search

Navigation